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El pirrol es un compuesto heterocíclico común con una química única. Se encuentra en una 
multitud de estructuras, y el alcance de su potencial en el campo terapéutico todavía está por 
verse. La comprensión de esta estructura nos ayuda en el desarrollo de nuevas síntesis y 
moléculas basadas en el pirrol. Las estructuras más reconocidas del pirrol se revisan de 
acuerdo a su eficacia farmacológica. En este trabajo, primero se profundiza lo que distingue 
al pirrol de otras moléculas aromáticas y cómo su estructura química afecta a las reacciones 
que puedan ocurrir. Esto se podrá aplicar a las reacciones de substitución del pirrol; estas se 
muestran de forma dinámica para entender los diferentes tipos de reacciones disponibles. 
Desde aquí se exploran varios métodos de síntesis del pirrol, desarrollando algunos de los 
más comúnmente utilizados: síntesis de Knorr, síntesis de Paal-Knorr, síntesis de Hantzsch y 
reacción de Barton-Zard. Finalmente, esta información se aplica para desarrollar la síntesis de 
tres productos farmacéuticos bien conocidos que contienen pirrol. 
ABSTRACT 
Pyrrole is a common heterocyclic compound with a unique chemistry. It is found in a 
multitude of structures, and the scope of its potential is still to be seen. Understanding this 
structure aids us in developing new syntheses and molecules based around pyrrole. Common 
pyrrole structures are revised to view which is their most frequent use.  In this work, we first 
delve into what differentiates pyrrole from other aromatic molecules and how its chemical 
structure affects the reactions that can take place. This knowledge can then be applied to 
common pyrrole substitution reactions; these are shown in a dynamic form so as to 
understand the different types of reactions available. From here exploring various pyrrole 
synthesis methods, further developing some of the most commonly used: Knorr pyrrole 
synthesis, Paal- Knorr synthesis, Hantzsch synthesis and Barton-Zard reaction. Finally, this 
information converges into understanding the synthesis of three well-known pyrrole- 




The aim of this dissertation is not only to create a work based on the principal subject area 
but to also apply knowledge from other areas of study and integrate them to create a well-
rounded analysis of the subject.  
In this work the principal area of study is organic chemistry, pyrrole is one of the most 
common nuclei in organic chemistry and so without understanding its structure, chemistry 
and reactivity we cannot develop its synthesis. A secondary area of study is pharmaceutical 
chemistry which together with organic chemistry allows for the development and 
understanding of the syntheses involved in poly substituted pyrroles, which can then be 
applied to the synthesis of current pyrrole-containing pharmaceuticals. The other subject area 
applied is biochemistry, since this work is regarding pharmaceuticals based on the pyrrole 
nucleus it is not only important to understand their synthesis but also the use of these 
pharmaceuticals in humans. The pyrrole nucleus is often found in natural products therefore 
it is important to recognise how metabolic pathways are used to create these structures since 





With numerous new pharmaceuticals coming onto the market yearly, it is ever more 
challenging to discover successful, economically viable molecules. One such way of identifying 
these potentially useful molecules is by examining the pharmacophores of other natural 
products or successful drugs, to try and expand on their structure and to identify efficient 
ways to synthesise them.  
One such molecule is pyrrole, a common chemical structure which stands out due to its 
repeated occurrence in natural and synthetic products as well as its particular chemistry. To 
be able to fully comprehend the scope of pyrrole it is essential that we first understand its 
unique structure and how this affects its synthesis. Following on from this we can explore 
common syntheses and how these are applied in well-known pharmaceutical products. 
Understanding these processes will allow us to be able to apply these methods to future 
endeavours, such as new chemical entities. 
2. OBJECTIVES 
This work aims to integrate the information acquired throughout the pharmacy degree to be 
able to apply it to a bibliographic research project.  
Specifically, this work aims to: 
 Develop an understanding of the presence of pyrrole in natural and synthetic 
molecules 
 Contextualise the structure, chemistry and reactivity of pyrroles to apply it to current 
examples of pyrrole-containing molecules  





3. MATERIALS AND METHODS 
This work is bibliographic and based on research found through literature regarding the topic 
of pyrroles. Firstly, a rough outline of the basis of the text was developed to structure the 
work. Based on this initial outline several sources were consulted. There is a wealth of 
information available regarding the chemistry of pyrrole since this entity has been known and 
researched for decades and so some of the information may be from older sources. 
Heterocyclic chemistry by J.A. Joule and K. Mills was of great use in this work as a starting 
point to understand the basic chemistry of pyrrole. From there SciFinder® was used to 
understand specific reactions further. Review articles of the current synthesis of pyrrole were 
consulted to have a further understanding of the scope of the syntheses available. From there 
three molecules were chosen to research their synthesis further. These molecules were 
chosen due to their variety of therapeutic use and effectivity in treatment; it was essential 
that the molecules chosen were both commercialised and successful. When researching these 
pharmaceutical entities, SciFinder® was once again used, referencing either academic articles 
or patents. Priority was given to industrial methods of synthesis rather than academia. 
PubMed® was a valuable resource when researching the use of these pharmaceuticals.  
Throughout this work primary, secondary and tertiary sources have been used, with keywords 
including pyrrole, pharmaceuticals, and names of specific reactions and products. Oftentimes 
the search was dependent on the section that was being developed. When researching the 
sections pertaining to the structure, chemistry and synthesis of pyrrole, secondary sources 
were predominantly used, most notably books on the subject of heterocyclic chemistry. As 
for the section on common examples of pyrrole products, primary sources were favoured. 
An important aspect of this body of work was the depiction of reactions related to pyrrole, 
for this ChemDraw® was used, offered by CRAI (Universitat de Barcelona). Part of the aim of 
this project was for it to be easily understandable for any person who has a foundational 
understanding of chemistry. Therefore, all diagrams are designed to be dynamic and easily 





4. RESULTS AND DISCUSSION 
4.1. Overview 
 
One interesting structure identified throughout nature and in a very diverse range of 
pharmaceuticals is pyrrole (Figure 1). This heterocyclic five-membered ring containing 
nitrogen has a molecular weight of 67.091 mg/ml, is less dense than water (0.968) and has no 
formal charge. It is a colourless liquid at room temperature though quickly turns brownish in 
contact with air, and it has a significant irritant odour and taste. Its boiling point is 129-131℃, 
when heated it emits toxic fumes. Its freezing point is -24℃. It is almost insoluble in water 




Figure 1: Pyrrole 
 
It is a naturally occurring product present in bone oil and coal tar - where it was first detected 
in 1834 by F. F. Runge. It is most notably found in porphyrins. Though they are not found 
naturally on their own, they are always part of a larger structure. Its name comes from the 
Greek pyrrhos, meaning red or fiery.2 This name likely derives from its reaction with 
hydrochloric acid, where when moistened with said acid it readily polymerises into dark red 




4.2. Pyrrole containing products  
 
Pyrrole is found in numerous natural and synthetic products, one of the most common 
structures is tetrapyrrole, four pyrroles joined together to create a scaffold often with a 
metallic ion in its centre. These structures are based on porphyrin which is synthesised 
through the condensation of four methanol or amine-substituted pyrroles. These create a ring 
structure which is subsequently reduced to give porphyrin.  
The starting reactant is 5-aminolevulinic acid, following a Knorr type reaction this molecule is 
cyclized, this produces porphobilinogen which is the pyrrole base for the structure. Four 
porphobilinogen are assembled to give a macro scaffold which, via specific enzymatic 
pathways, will go on to give different products depending on the porphyrin structure required 
(Scheme 1).3  
From this structure Heme b (Scheme 1), found in oxygen transport proteins,4 is produced in 
humans as well as other species. Factor 430 (Scheme 1) is also derived from this structure; it 
is the prosthetic group of the enzyme methyl-coenzyme M reductase,5 found in only some 
Archaea and thought to be involved in reverse methanogenesis. It is also the scaffold for 
chlorophyll a4 (Scheme 1), a green pigment found in plants, algae and bacteria which is crucial 
for photosynthesis. Other notable products are bilirubin, a degradation product of heme, and 
cobalamin, an essential vitamin required for DNA synthesis, metabolism as well as other vital 










Pyrrole is also present in many marine organism metabolites (Figure 2a); such examples are 
Storniamide A which is an inhibitor of multidrug resistance, a phenomenon where a cell is 
inherently resistant to commonly used drugs, complicating the patient’s treatment. 
Marinopyrrole A is useful against methicillin-resistant Staphylococcus aureus strains. Halitulin 
is a cytotoxic natural product isolated from a marine sponge (Haliclona tulearensis).6 These 
substances can potentially lead to useful therapeutic molecules. 
Lead products for new drugs are usually derived either from natural products with interesting 
therapeutic properties - as above - or de-novo, where newly synthesised molecules are tested 
to determine if they have any therapeutic properties. One example is BM 212 (Figure 2a), a 
promising lead product with anti-bacterial and anti-fungal properties. 
Also shown are several commercially available drugs used to treat a variety of diagnostics 
(Figure 2b). Atorvastatin is frequently used to lower cholesterol levels, and one of the world’s 
most successful drugs. Sunitinib is a neoplastic drug used to treat renal cell carcinoma and 
gastrointestinal stromal tumour. Ketorolac and Tolmetin are anti-inflammatory drugs; the 
former is used for acute moderate to severe pain with analgesic effects similar to those shown 
by opioids. The latter, Tolmetin, can be used long-term for acute flare-ups of rheumatoid 
arthritis and osteoarthritis,7 and to treat pain associated with these conditions. Both these 
anti-inflammatory drugs are COX inhibitors, which are involved in prostaglandin formation. 
Finally, in Figure 2c optoelectrical materials are also shown, pyrrole has been a source of much 
attention for material scientists. BODIPY dyes are chemically inert and fluorescent, with great 
potential use in imaging. Electrochromic conductive polymers can be formed with a pyrrole 








Figure 2: Examples of pyrrole-containing product. (a) Natural products (b) Pharmaceuticals (c) Optoelectrical materials 
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4.3. Structure of Pyrrole 
Pyrroles have unique chemistry since the nitrogen atom within the pyrrole molecule is sp2 
hybridised, its unshared electron pair occupies p-orbitals. Consequently, pyrrole’s electron 
cloud consists of overlapping p-orbitals (Figure 3).2 It is important to recognise that the 




Figure 3: Pyrrole orbital structure 
Their aromaticity is not particularly stable, and therefore they react far more rapidly than 
even electron-rich aromatic rings with substances like air, or acid.8 This electron structure also 
means that pyrrole, unlike other amines, is a weak base since its lone pair of electrons is not 
readily available. They can react with both nucleophiles and electrophiles. The most 
nucleophilic site is on hydrogen, though an electron-withdrawing group is required for the 
reaction to take place. Electrophilic attack occurs at C2 since this is the site of most electron 
density. The electron-rich nature of pyrroles has a profound effect on ring substituents since 
they react far more rapidly than other normal arenes. 
Pyrrole is electrically different from its carbon-based counterpart due to the presence of 
nitrogen. Where cyclopentadiene anion has five equivalent contributing structures, in which 
each carbon is equivalent and so carries one-fifth of the negative charge (Figure 4).  
 
 






In pyrrole the structure is electrically neutral because of the higher nuclear charge on 
nitrogen, this means that it does not have five equivalent mesomeric forms: one of its forms 
has no charge separation, and the other two pairs are equivalent forms in which there is 
charge separation (Figure 5).8 
These forms do not contribute equally with the importance being a > c+e > b+d.  
This produces a notable electron density drift away from the nitrogen towards the ring 
carbons and is responsible for the dipole moment of the molecule, which overpowers over 
the inductive effect of nitrogen.2 
 
 
Figure 5: Pyrrole resonance and how it affects bond length and the dipole moment 
 
Pyrrole is referred to as electron rich due to said electronic drift; away from nitrogen and 
towards the ring carbons. This is due to the mesomeric effect (contribution of the various 
mesomeric forms shown above), which places partial negative charges on carbon, 
overpowering the inductive effect of nitrogen to create a dipole directed away from the 
nitrogen. A consequence of this dipole is that the 3,4 C-C bond is considerably longer (1.43Å) 







4.4. Pyrrole Chemistry 
 
It is essential to comprehend pyrrole's set of reaction mechanisms since they differ from that 
of benzene. Understanding this chemistry allows us to develop appropriate synthetic routes 
for more complex products based around the pyrrole scaffold. 
Pyrroles are resistant to nucleophilic attack though are very susceptible to electrophilic 
reactions due to their 'π-excessive' structure. As mentioned previously, they readily 
polymerise in the presence of a strong acid, meaning that typical aromatic substitution 
reactions cannot be used. Though, polymerisation can be avoided by the addition of an 
electron withdrawing group.8  
Halogenation 
Attempts to halogenate pyrroles often result in tetrahalo-pyrroles (Scheme 2, Method B) 
since pyrroles readily react with halogens, and the fully substituted product is very stable. 
Under controlled conditions, mono-substitution of pyrrole can take place8 (Scheme 2, Method 
A). As with other electrophilic additions, halogenation occurs at the C2 position, though if a 
large group is added to the nitrogen (such as TIPS - triisopropylsilyl) halogenation can occur 
at the C3 position. This can be a useful method for further functionalization of the less reactive 
3-position. 
Nitration 
Pyrroles can be nitrated by reacting with acetyl nitrate at low temperatures, predominantly 
giving 2-nitropyrrole9 (Scheme 2, Method C). The reaction can be directed towards a 3-
nitropyrrole by adding a large substituent to the nitrogen (such as triisopropylsilyl), which can 
be easily removed with TBAF (tetrabutylammonium chloride) (Scheme 2, Method D). 
Acylation 
The Vilsmeier reaction was developed to carry out acylation without the need of a strong acid, 
as in Fridel-Crafts. It uses an N,N-dialkyl-chloromethyleneiminium cation, with selectivity for 
the α position.2 An iminium salt is formed, which is then hydrolysed to give an aldehyde 
(Scheme 2, Method F). Again, if a large substituent is added to the nitrogen, the reaction will 
lose its selectivity and take place on the β position. 
Alkylation 
Alkylation cannot be carried out by a simple alkyl halide. An acidic catalyst is used – ensuring 
it does not cause pyrrole to polymerise – together with an alkene carrying an electron-





Side chains can easily be added to the nitrogen atom in pyrrole by using a halogenated 
reactant and a catalyst. Shown is the introduction of a simple alkyl group (Scheme 2, Method 
G). This reaction is not only useful for introducing substituents, but also for protecting the 
nitrogen on pyrrole. By adding a phenyl substituent we can maintain pyrrole’s aromaticity 
while avoiding any reaction on nitrogen. This reaction is also used when introducing TIPS, a 
group which due to its volume allows the α-selective reactions to take place on beta.  
Reactions with nucleophilic reagents  
Pyrroles only react by substitution with nucleophilic reagents when there is a leaving group 
present on one (or more) of the carbons. An example of this is shown, where the nitrogen has 
been protected, and there is a nitro group present on both α positions of the pyrrole. In such 
cases, pyrrole can react with a nucleophilic reagent (Scheme 2, Method H).                                                                                                                      
 
 





4.5. Methods for the synthesis of pyrroles 
A vital part of developing pyrrole-based pharmaceuticals is their synthesis, particularly how 
to synthesise polysubstituted pyrroles. As we have previously seen, the range of reactions 
that pyrroles can undergo is limited, so it is often beneficial to incorporate substituents during 
the synthesis of pyrrole. Figure 6 shows an overview of common pyrrole retrosynthesis, each 
is a pathway to obtaining polysubstituted pyrroles. 
 
Figure 6: Common retrosynthesis of pyrrole 
Figure 6, method 1 is a reductive ring contraction;10 this is carried out through either chemical 
or electrochemical reduction. It is essential that pyridazine is substituted, preferably with 
electron withdrawing groups. Figure 6, method 2 shows a catalyst-led ring closure, the metal 
involved can be Pd, Ru or Ir.11 Figure 6, method 3 is a McMurry-type coupling,12 using low-
valent titanium, the carbonyls are reduced to alkenes. All substituents must be hydrogen or 
carbon-based, except R2 where an amine or ether is also possible. Figure 6, method 4 depicts 
two possibilities; the first van Leusen synthesis13 where R5 is Tos (a toluenesulfonyl group), 
and Y is hydrogen.13 A later development of this reaction is Barton-Zard,14 where R5 is any 
substituent and Y is a nitro group. Figure 6, method 5 is a converging coupling15 of an enone 
and a secondary amide. Figure 6, method 6 depicts a Hinsberg type reaction,16 under basic 
conditions, pentasubstituted symmetrical pyrroles are formed. Figure 6, method 7 is based 
on the cycloaddition of münchones17 (1,3-oxazolium-5-ones) to alkenes or alkynes. 
15 
 



































































Figure 7: Retrosynthesis of pyrrole based on 1,4-dicarbonyl 
 
In Figure 7, method 1 we see how various combinations of double or triple bonds can easily 
be converted into pyrrole using a metallic catalyst,18 such metals include Au, Pd, Ir, or Cr. 
Figure 7, method 2 is the addition of isocyanide to 1-azabutene19 and requires AlCl3, this 
reaction is useful when forming 2-aminopyrroles. Figure 7, method 3 shows Knorr pyrrole 
synthesis,20 a method commonly used; it consists of the condensation of α-aminoketone with 
a ketone. Trofimov pyrrole synthesis21 is shown in Figure 7, method 4, this synthesis has the 
same disconnection as Knorr but instead uses ketoximes and alkynes to give 4,5-substituted 
pyrrole, in the presence of a strong base. Figure 7, method 5 is Hantzsch pyrrole synthesis22 
and it is the condensation of α-haloketones or aldehydes with β-ketoesters. Figure 7, method 
6 is the nitro Michael approach.23 Though typically used to form indoles, this method has been 
used to produce polysubstituted pyrroles. It involves intramolecular cyclization of γ-
nitroketones. Paal-Knorr,24,25 shown in Figure 7, method 7, involves an acid-catalysed 
condensation of ammonia or a primary amine with 1,4-dicarbonyl compounds, this is the 
parent compound for all the reactions shown in Figure 7. Finally, Figure 7, method 8 shows 
the Piloty-Robinson synthesis26 where two equivalents of a ketone or aldehyde are reacted 
with hydrazine, producing a symmetrical polysubstituted pyrrole, where R2 and R3 are the 
same as R5 and R4 respectively. 
16 
 
Knorr pyrrole synthesis 
Initially reported in the late 1800s this widely used reaction consists of the condensation of 
an α-aminocarbonyl with a ketone or ketoester20 (Scheme 3), this second component must 
possess a methylene group alpha to a carbonyl. A reducing agent, such as Zinc-acetic acid, is 
required. One issue with this method is the α-aminocarbonyl tendency to self-condensate, a 
way of avoiding this is by preparing them in the presence of the second component, often 
using the relevant oxime. Several variations of this mechanism have been developed to 
improve on issues associated with it such as, its lack of regioselectivity with unsymmetrical 
beta-diketones, often symmetrical beta-diketones are used. 
 
Scheme 3: Knorr pyrrole synthesis 
 
R4 must be an alkyl or aryl, and R5 can be H, aryl or carboxylic acid. R3 must be an electron 
withdrawing group (such as an ester), and R2 may be H, alkyl, aryl or CO2R.15 The initial 
carbonyl is reacted with a nitro group to give an oxime; this is to introduce nitrogen, while 
also avoiding self-condensation. The oxime is reduced to give the initial α-aminoketone. The 
amine attacks the carbonyl on the second component, condensing to give an imine. The imine 
tautomerizes to an enamine, which is then cyclized, and water eliminated. Finally, the 
electron structure is rearranged so that the aromaticity of pyrrole is established. 
17 
 
Paal Knorr Synthesis 
 
This synthesis involves the reaction of ammonia or a primary amine with a 1,4-dicarbonyl 
compound, via an acid catalysed condensation.24,25 It yields a polysubstituted pyrrole. The 
method was initially reported in 1884 though its mechanism was not understood until the 
1990s.27 There have been several variations to this synthesis, improving its speed and 
regioselectivity. An alternative to using ammonia is hexamethyldisilane on alumina, or 
ammonia can be produced in-situ using magnesium nitride in methanol.  
 
Scheme 4: Paal-Knorr synthesis 
This reaction allows the substitution of the nitrogen in pyrrole, in the R1 position either an 
alcohol or any carbon-based substituent can be introduced. If ammonium hydroxide is used, 
an N-unsubstituted pyrrole will be produced. As for the other R groups, R2 and R5 must be 
either hydrogen or carbon-based, whereas R3 and R4 can be either of these as well as a 
carboxylic acid derivative. The amine attacks one of the carbonyls, this product then 




Hantzsch pyrrole synthesis 
 
This method allows the synthesis of an ester-substituted pyrrole.22 Initially, it was reported 
that this was the only substitution that could take place, but it has been demonstrated that 
through this method R4 and R5 can also be added. In this scheme, an equimolar mixture of a 
β-ketoester (or β-diketone) and an α-haloketone or aldehyde are refluxed in the presence of 
aqueous ammonia. The ester is converted into an enamine, which then reacts with the 
ketone. 
An amine can be used instead of ammonia, to give an N-substituted pyrrole but this produces 
a very low yield, and so it is not frequently used.  
 
Scheme 5: Hantzsch synthesis 
The amine (NH4) attacks the β-carbon of the ketoester, forming an enamine. The enamine 
then attacks the carbonyl of the second component. The loss of water produces an imine, this 
undergoes an intramolecular nucleophilic attack, removing the halogen and closing the ring. 






This route leads to a polysubstituted pyrrole with a ketone on C2. It is an expansion on the van 
Leusen synthesis. It comprises of the reaction of a nitroalkene with an α-isocyanoacetate 
ester under basic conditions.14 The non-nucleophilic base involved can be KOtBu, DBU or 
guanidine bases. The nitro group activates alkenes, leading them towards Michael addition 
and making them good leaving groups. 
 
Scheme 6: Barton-Zard Reaction 
The reaction is divided into five steps; first, the α-isocyanoacetate is enolised, which allows 
the Michael-type addition of the nitroalkene. Next, there is an intramolecular cyclization, with 
the base catalysing the elimination of the nitro group. Then there is a rearrangement of 









Atorvastatin (Figure 8) is an inhibitor of HMG CoA reductase, an enzyme involved in the 
synthesis of cholesterol in mammals. The inhibition of this enzyme leads to a reduction in 
total cholesterol levels and therefore is useful in the prevention of heart disease. Atorvastatin 
is part of a much larger groups of statins – all inhibitors of HMG CoA reductase – though they 
all have very different chemical structures, their commonality being an opened-lactone 
(shown in blue). Within this group of statins, atorvastatin is the most prescribed due to its 
lower incidence of serious side-effects.28 
 
Figure 8: Atorvastatin Figure 9: Compactin 
Atorvastatin was first commercialised as Lipitor® by Pfizer in 1996. From its release till the 
end of its patent, Lipitor® broke records by becoming the world’s bestselling pharmaceutical 
of all time, amassing roughly $125 billion in sales over almost 15 years.  
The drug is based on a fungal metabolite named compactin (Figure 9). The potential use of 
this metabolite was known as the first statin was already on the way to market. With 
structure-activity studies, the Warner-Lambert company found that 3- and 4- substituted 
pyrroles had an increased potency compared to classical 2- and 5- substituted pyrroles.29 The 
only structure that is conserved from the original lead molecule is the lactone (shown in blue). 
Within statins, there are several heterocycles, but atorvastatin is the only to contain a pyrrole 
structure.  
Substituted pyrrole rings by ZnCl2-catalysed condensation reactions were limited when trying 
to synthesise more complex structures such as atorvastatin. Through several trials, it was 
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found that creating the central pyrrole scaffold then adding the necessary side chain was the 
most effective synthesis. 
Initially, a [3 + 2] cycloaddition of an acetylene component with an amino acid was tested, but 
this led to an undesired isomer, with the undesired regioisomer being the favoured product 
(4:1) causing a very low yield. However, by carrying out the analogous reaction and starting 
with a fluoride substituted phenyl (Scheme 7), instead of an iso-butyl group on the amine 
structure, led to a completely regiospecific product, though it still gave a moderate yield.30 
 
Scheme 7: Synthesis of pyrrole nucleus via [3+2] cycloaddition 
By modifying the last step to create a münchone, it was easier to establish the desired 
regiospecific structure so that a side chain could be synthesised and added. By adding 
























Scheme 8: Addition of sidechain after [3+2] synthesis 
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A few years after the initial patent, a second patent was issued to synthesise the pyrrole 
scaffold using a different approach (Scheme 9). This new method is based on the Paal–Knorr 
synthesis previously mentioned, first, the substituted 1,4-diketone is set up through 
condensation and alfa-substitution. Following on from this a substituted amine is introduced, 
and the remainder of the scaffold constructed. Lastly, the structure is refluxed with toluene 
under mildly acidic conditions where the pyrrole is formed with a much more desirable yield. 
 
Scheme 9: Actual synthesis of atorvastatin 
To further improve the yield the last step was altered so that the side chain can be added 
(Scheme 10). The side chain is synthesised via fermentation since this gives the required 
stereochemistry. Once the final structure is obtained the acetal is cleaved to give two 











Sunitinib (Figure 10), commercialised as Sutent®, is a multi-targeted tyrosine kinase (RTK) 
inhibitor used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant 
gastrointestinal stromal tumour (GIST);31 it is considered a second-line treatment.  
 
 
Figure 10: Sunitinib 
 
Tyrosine-kinase receptors are high-affinity cell surface receptors found throughout the 
human body. This includes platelet-derived growth factor (PDGF-Rs) and vascular endothelial 
growth factor receptors (VEGFRs) the inhibition of these targets reduces tumour 
vascularisation, resulting in apoptosis and so tumour shrinkage.31 Since sunitinib produces 
tumour shrinkage it is useful in increasing life expectancy though it is not able to eliminate 
the tumour - hence it is not a cure. One of the advantages of sunitinib is its route of 
administration since it is an oral drug; it can increase the quality of life as it does not require 
hospitalisation for its administration. Since it is multi-targeted with low specificity it is 
associated with many side effects, though these are considered to be manageable.32 
Sunitinib consists of a complex pyrrole-substituted 2-indolinone core. It is synthesised by 
nitrosation of tert-butyl acetoacetate, producing an oxime which is then reduced by zinc to 
give an unstable aminoketone intermediate, which allows for a Knorr pyrrole synthesis. An 
imine is produced, tautomerized and consequently cyclized to produce the substituted 
pyrrole scaffold. The tert-butyl ester is then removed to yield the fully elaborated pyrrole 
aldehyde. From here an aldol condensation between the pyrrole scaffold and a 2-indolinone 





Scheme 11: Synthesis of sunitinib 
An alternative synthesis proposed by Pfizer, which produces a higher yield, is shown below. It 
introduces the amide side chain earlier since it is based on the starting reactant of the 
synthesis. Said reactant is a substituted oxetane, with a carbonyl and an alkene group. This is 
reacted with N,N-diethylethane-1,2-diamine, resulting in a β-ketoamide. The pyrrole is then 
formed, again using the Knorr synthesis as seen in Scheme 12. Deprotection and 
decarboxylation of the remaining tert-butyl ester produce the desired pyrrole intermediate, 
which using Vilsmeier reagent undergoes a formal acylation. This intermediate is immediately 
reacted with a 2-indolinone fragment30 (same reactant as seen above) to give sunitinib. 
 





Ketorolac (Figure 11) is a short term NSAID (a non-steroidal anti-inflammatory drug) and is 
usually not prescribed for longer than five days. It is mostly used for its analgesic effect, 
treating acute moderate to severe pain. Its analgesic potency is similar to that of opioids 
though does not cause respiratory problems; therefore it is useful in neonatal pain control.33 
The biological activity of ketorolac tromethamine is associated with the S-form. It is an 
inhibitor of both cyclooxygenase-1 (COX-1) and cyclooxygenase 2 (COX-2).34 
 
Figure 11: Ketorolac 
As well as being a systemic analgesic it is also used in ophthalmology, aiding to maintain 
mydriasis so that cataract surgery can be carried out. It can also be used for pain associated 
with corneal abrasions.35 
Ketorolac can only be used for short periods due to its increased risk of causing kidney 
damage.34 In high-risk patients, this drug should be avoided (such as patients over 65 years 
old). 
Unlike other pyrroles we have seen, ketorolac is a much simpler molecule with fewer 
substitutions meaning that more traditional methods of synthesis can be used. It is crucial 
that the benzoyl group be introduced towards the end of the sequence to prevent 
electrophilic reactions to the C4 position of the pyrrole. The carboxylic acid will also need to 
be protected since it is very reactive. 
The sequence below is an example of the reaction which is described in the original patent of 
ketorolac, assigned to Syntex (USA) Inc.36 
In this the starting reactant is pyrrole (Scheme 13), this is converted to a pyrrole Grignard 
reagent using an alkyl-magnesium halide. The resulting reactant is combined, in excess, with 
a dihalobutanamide, this is a simple substitution reaction. The resulting product, 
pyrrolylbutanamide, is then cyclized with a quaternary amine salt catalyst and is obtained by 
crystallisation with water. A modified Vilsmeier-Haack arylation is carried out, enabling the 
addition of the second benzene. This product is obtained by acidification. Finally, the 




Scheme 13: Synthesis of ketorolac 
 
The dihalobutanamide side chain is available commercially or can be incorporated as a 
previous step to the synthesis of ketorolac. An N-alkyl-arylamine is treated with a 2-bromo-4-
chlorobutanoyl bromide in the presence of a tertiary amine base and an organic solvent 











The pyrrole ring system is a key feature in many products, ranging from anti-hyperlipidemic 
pharmaceuticals, to basic biochemical structures for photosynthesis, to fluorescent dyes, to 
marine life metabolites. The diversity of these properties shows such a wide range that 
pyrrole is an attractive structure when developing new chemical entities.  
In this work an overview of key components of pyrrole structure, chemistry and synthesis 
have been highlighted and discussed. From this work a basis is built to be able to apply said 
methods to new compounds and be able to effectively synthesise pyrrole.  
The application of key chemistry components has been highlighted in the context of the 
synthesis of three important pharmaceutical products. Firstly, atorvastatin, a very profitable 
drug whose synthesis is based on the Paal-Knorr mechanism. Sunitinib, an effective neoplastic 
drug following the Knorr synthesis. Finally, ketorolac a potent analgesic which is synthesised 
following basic substitution methods to create a molecule of much greater complexity. 
From this work, we can ascertain not only pyrrole’s chemistry and reactions but also the 
importance of thoroughly understanding the structures uses before being able to apply it to 
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